Name(s) and Address of Registered Shareholder(s)

丹诺医药
TENNOR THERAPEUTICS

TenNor Therapeutics (Suzhou) Limited
丹諾醫藥（蘇州）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6872)

8 June 2026

Dear Shareholder

Arrangements on Dissemination of Corporate Communications

INTRODUCTION

Pursuant to Rule 2.07A of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the articles of association of TenNor Therapeutics (Suzhou) Limited (the "**Company**"), the Company will disseminate its future corporate communications of the Company (the "**Corporate Communications**[1]") to its Shareholders[2] electronically and only send the Corporate Communications in printed form to the Shareholders upon request.

ARRANGEMENTS

1. Actionable Corporate Communications[3]

The Company will send the Actionable Corporate Communications to its Shareholders individually in electronic form by email. If the Company does not possess the email address of a Shareholder or the email address provided is not functional[5], the Company will send the Actionable Corporate Communications in printed form together with a request form for soliciting the Shareholder's functional email address to facilitate electronic dissemination of Actionable Corporate Communications in the future.

2. Corporate Communications

The Company will make the Corporate Communications available on its website (www.tennortherapeutics.com) and the Stock Exchange's website (www.hkexnews.hk).

The Company will not send a notice of publication of the Website Version[5] of the Corporate Communications to its Shareholders. The Shareholders are encouraged to proactively monitor the availability of all future Corporate Communications on the websites and access the Website Version of the Corporate Communications by themselves.

3. Provision of the Shareholder's Email Address to the Company

In support of electronic communication by email, the Company recommends its Shareholders to complete the request form by scanning the above QR Code which is valid by 7 July 2026. Should the Shareholders, for any reason, have difficulty in gaining access to the request form, they may provide the Company with their functional email address at any time in the future by reasonable notice (i.e. not less than 7 business days) in writing to the Company's H share registrar and transfer office, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong or by email to 6872-ecom@vistra.com.

It is the responsibility of the Shareholders to provide email address that is functional. If the Company does not possess the email address of a Shareholder or the email address provided is not functional, the Company will act according to the above arrangements. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications to the email address provided by a Shareholder without receiving any "non-delivery message".

4. Request for the Corporate Communications and the Actionable Corporate Communications in printed form

For those Shareholders who wish to receive a printed version of all future Corporate Communications and Actionable Corporate Communications or, if for any reason, have difficulty in gaining access to the Company's website, the Company will, upon receipt of request in writing by the Shareholder to the Company's H share registrar and transfer office, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong or by email to 6872-ecom@vistra.com, send future Corporate Communications and/or the relevant Actionable Corporate Communications (as the case may be) to such Shareholders in printed form free of charge.

Please note that the preference in receiving Corporate Communications in printed form of a Shareholder will be valid unless being revoked or superseded or until expired at the end of each financial year of the Company (whichever is earlier). Further request in writing will be required if a Shareholder prefers to continue receiving printed copy of future Corporate Communications and Actionable Corporate Communications.

Details of the arrangements (i) for dissemination of the Corporate Communications; and (ii) for requesting printed copy of the Corporate Communications are published under the section "Investor Relations – Announcements & Notices" in the Company's website (www.tennortherapeutics.com). For any queries in relation to this letter, please call the Company's H share registrar and transfer office, Tricor Investor Services Limited, at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding Hong Kong public holidays, or by sending an email to 6872-ecom@vistra.com.

Notes:

1. Corporate Communications refer to any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

2. Holder(s) of the H Share(s) of the Company.

3. Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders of the Company on how they wish to exercise their rights or make elections as the Company's Shareholders.

4. It is the responsibility of a Shareholder to provide email address that is functional. The Company will be considered to have complied with the Listing Rules if it sends the Actionable Corporate Communications to the email address provided by a Shareholder without receiving any "non-delivery message".

5. The electronic version of the Corporate Communications being published, in both English and Chinese, on the Company's website and the Stock Exchange's website.

By order of the Board
TenNor Therapeutics (Suzhou) Limited
Dr. Ma Zhenkun
Chairman of the Board, executive Director,
chief executive officer and general manager